HAYA Therapeutics, SA

Long non-coding RNA (lncRNA) is an emerging therapeutic modality that may offer actionable novel targets in a variety of disease settings, and Eli Lilly and Company , already a leader in obesity and

Private biopharmaceutical companies raised more than $1bn from venture capital, seed financing and government investments during the past week, including Eliem Therapeutics, Inc. , which said on 24 M